Nashville, Tenn. - November 6, 2003 - Nashai Biotech, LLC, a product research, development and procurement company for nutritional supplements, over-the-counter medications and active pharmaceutical ingredients (APIs), today announced that its president and CEO Michael Vaughn will participate in the 12th Invest in Japan Study Program sponsored by the Japan External Trade Organization (JETRO), November 9-15, 2003, Tokyo, Japan. An exclusive group of six companies from all parts of the world, representing a select set of industries including medical devices and services, was invited by JETRO to participate in the program, which is designed to encourage business initiatives.
Vaughn will represent the company on the all-expense-paid tour that includes field trips to various regions of Japan to study the business climate, visits to offices and factories/R&D centers to explore appropriate locations, business and social meetings with Japanese companies, and seminars.
"Nashai Biotech is honored by this invitation and looks forward to expanding its international presence as a developer and marketer of nutraceuticals and prescription products," said Vaughn, co-founder of Nashai, who currently oversees the development and launch of new products worldwide and directs operations in Nashville, TN and Irvine, CA, as well as manufacturing plants in Shanghai, China. "Japan represents a thriving and potentially lucrative business environment for expanding Nashai's growing network for the manufacturing and worldwide distribution of cost-effective, meaningful solutions for preventive healthcare."
Over the past few years, Nashai has developed processes for making and using theaflavins from tea. In June 2003, Nashai introduced its flagship product, Teaflavin®, an all natural, caffeine-free product which is available to consumers as a 375 milligram daily capsule. Results of a clinical study published in the Archives of Internal Medicine (6/23/03) documents the effectiveness of a theaflavin-enriched tea extract to lower LDL cholesterol
(LDL-C) by 16.4 percent, with no adverse effects.
Nashai currently maintains a robust presence in Asia, with an eye toward additional expansion in Japan. In December 2002, the Chinese Ministry of Health issued a health food license to Nashai Biotech, representing the first license granted by the Chinese government in this category and the first license issued for theaflavins. This license authorizes Nashai Biotech to manufacture and sell its product, Teaflavin®, in China for the treatment of cardiovascular disease, especially cholesterol reduction.
International agreements for distribution of Teaflavin® are also underway in England, Canada, India, New Zealand, Australia, and Puerto Rico, building upon existing US and China marketing contracts that will bring Teaflavin® to millions worldwide.
About Nashai Biotech, LLC
Headquartered in Nashville, Tennessee with offices in Irvine, California and Shanghai, China, Nashai Biotech, LLC (www.nashai.com) produces patented, new generation formulas and ingredients based upon compelling scientific evidence. Nashai researches, develops and produces novel ingredients, converted into dietary supplements, over-the-counter medicines and active pharmaceutical ingredients, for distribution to the consumer by pharmaceutical and natural products companies with well-established marketing and distribution networks. Nashai Biotech has been accepted for membership in the Council for Responsible Nutrition, one of the dietary supplement industry's leading trade associations.